EG 427

Focus: EG 427 is a French biotechnology company specializing in pinpoint gene therapy, currently focused on early-stage clinical development in neurogenic and urological indications.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About EG 427

AI assessmentNot Hiring

No open roles listed right now. Follow EG 427 to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EG110A

Neurogenic Detrusor Overactivity

Phase 1/2

Clinical Trials (1)

NCT06596291Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

Phase 1/2

Help build intelligence for EG 427

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in precision gene therapy, a high-growth modality with significant unmet need in neurology and urology
Early-stage pipeline positioning offers direct impact on drug development and potential for rapid advancement into leadership roles
Based in Paris with exposure to European regulatory pathways and biotech innovation hubs

Watch Out For

Pre-revenue stage with unknown funding runway and cash position—financial stability and long-term job security cannot be assessed
Minimal hiring (1 open role) and no published data on team size, organizational structure, or growth trajectory suggest very early-stage operations
No Phase 3 programs, publications, or recent news disclosed—limited visibility into scientific progress, clinical momentum, or company milestones

Generated by Claude from EG 427's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Urodynamics

Urinary Bladder, Overactive

Phase 1/2

Clinical Trials (1)

NCT07227285Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo